Introduction: Post-traumatic stress disorder (PTSD) has been associated with immune disturbances, including a higher incidence of infections and autoimmune diseases as well as a net pro-inflammatory state. Natural killer (NK) cells, a key component of the innate immune system, have been less well-studied in PTSD despite their importance in immunity.

Methods: We studied two independent samples of combat-exposed male war veterans with or without PTSD, the first ("Discovery Sample") to generate hypotheses, and the second ("Validation Sample") to replicate the findings. The Discovery Sample was comprised of 42 PTSD subjects and 42 controls. The Validation Sample was comprised of 25 PTSD subjects and 30 controls. Participants had fasting, morning blood samples collected for examination of the frequency of NK cell subsets, determined by flow cytometry. The current and lifetime Clinician Administered PTSD Scale (CAPS) was used to assess symptom severity. Statistical analyses were adjusted for age and BMI.

Results: PTSD subjects compared to controls had (i) a significantly higher relative frequency of atypical CD56(-)CD16(+) NK cells in the Discovery Sample (p=0.027), which was replicated in the Validation Sample (p=0.004) and the combined sample (p<0.001), and (ii) a non-significantly lower relative frequency of CD56(bright)CD16(-) NK cells in the two samples (p=0.082; p=0.118), which became statistically significant in the combined sample (p=0.020). Further, within subjects with PTSD of both samples, the relative frequency of atypical CD56(-)CD16(+) NK cells was near significantly positively correlated with lifetime PTSD severity (p=0.074).

Discussion: This study is the first to characterize NK cell subsets in individuals with PTSD. The results suggest that combat-exposed men with PTSD exhibit an aberrant profile of NK cells with significantly higher frequencies of an atypical population of CD56(-)CD16(+) cells and possibly lower frequencies of the functional CD56(bright)CD16(-) NK cell subsets. Higher proportions of dysfunctional CD56(-)CD16(+) cells have been reported in certain chronic viral infections and in senescent individuals. It is possible that this could contribute to immune dysfunctions and prematurely senescent phenotypes seen in PTSD.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbi.2016.03.021DOI Listing

Publication Analysis

Top Keywords

ptsd subjects
12
atypical cd56-cd16+
8
natural killer
8
killer cells
8
ptsd
8
ptsd associated
8
symptom severity
8
discovery sample
8
sample comprised
8
comprised ptsd
8

Similar Publications

The burnout phenomenon is a subject of considerable interest due to its impact on both employee well-being and scientific inquiry. Workplace factors, both intrinsic and extrinsic, play a pivotal role in its development, often leading to job dissatisfaction and heightened burnout risk. Chronic stress and burnout induce significant dysregulation in the autonomic nervous system and hormonal pathways, alongside structural brain changes.

View Article and Find Full Text PDF

Dysfunction in fear and stress responses is intrinsically linked to various neurological diseases, including anxiety disorders, depression, and Post-Traumatic Stress Disorder. Previous studies using in vivo models with Immediate-Extinction Deficit (IED) and Stress Enhanced Fear Learning (SEFL) protocols have provided valuable insights into these mechanisms and aided the development of new therapeutic approaches. However, assessing these dysfunctions in animal subjects using IED and SEFL protocols can cause significant pain and suffering.

View Article and Find Full Text PDF

: Post-traumatic stress disorder (PTSD) is a debilitating condition worldwide. The limited effectiveness of current psychological and pharmacological treatments has motivated studies on meditation techniques. This study is a comprehensive, multiple-treatments meta-analysis comparing the effectiveness of different categories of meditation in treating PTSD.

View Article and Find Full Text PDF

Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.

Am J Psychiatry

January 2025

Institute for Advanced Diagnostics and Treatment, Sheppard Pratt Health System, Baltimore (Aaronson, Miller, LaPratt, Swartz, Shoultz, Lauterbach); Department of Psychiatry, University of Maryland, Baltimore (Aaronson, van der Vaart, Lauterbach); VA Palo Alto Health Care System and Department of Psychiatry and Behavioral Sciences Stanford University School of Medicine, Palo Alto, CA (Suppes); Departments of Psychiatry and Radiology, Columbia University, New York (Sackeim).

Article Synopsis
  • The study focused on evaluating the safety and effectiveness of psilocybin for patients with severe treatment-resistant depression (TRD), who had not benefited from at least five previous treatments.
  • Conducted over 12 weeks at Sheppard Pratt Hospital, patients received a single 25 mg dose of synthetic psilocybin and underwent therapy sessions before and after dosing, assessing their depression levels mainly with the Montgomery-Åsberg Depression Rating Scale (MADRS).
  • Results showed significant reductions in depressive symptoms at both 3 weeks and 12 weeks post-treatment, indicating psilocybin’s potential as a viable option for individuals with severe TRD, although those with comorbid PTSD experienced less improvement.
View Article and Find Full Text PDF

Background: Low-grade systemic inflammation has been reported in many psychiatric diseases and is described as a non-severe state of the inflammatory response. Post-traumatic stress disorder (PTSD) is a chronic psychiatric disorder characterized by symptoms of avoidance, re-experiencing and hyperarousal that develop secondary to a serious traumatic event. The trauma itself creates psychological and biological changes in the individual, apart from PTSD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!